Patents Examined by Laura B Goddard
  • Patent number: 10604786
    Abstract: The present invention relates to a method for determining or predicting the response of a patient diagnosed with melanoma to targeted pharmacotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with melanoma to specific medicaments. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles and inhibitions thereof by drugs in samples of said patients.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: March 31, 2020
    Assignee: PAMGENE BV
    Inventors: Robby Ruijtenbeek, Liesbeth Coosje Hovestad-Bijl
  • Patent number: 10604571
    Abstract: The present invention provides an antibody having cross-linking ability against human Sema3A and mouse Sema3A. The antibody of the present invention can be used as therapeutic antibody drugs for inhibiting Sema3A in various cancers in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as a therapeutic agent for associated diseases in addition to an anti-cancer drug. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas through inhibition of Sema3A function due to high anti-Sema3A binding, and inhibits the movement of cancer cells through inhibition of phosphorylation of ERK among Sema3A lower signaling substances.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: March 31, 2020
    Inventors: Do Hyun Nam, Yong Jae Shin, Jae Hyun Lee
  • Patent number: 10597453
    Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulator are disclosed. Also disclosed is a method of treating proliferative disorders with the antitumor antagonists.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: March 24, 2020
    Assignee: Gensun Biopharma, Inc.
    Inventors: Jackie Sheng, Bo Liu, Margaret Karow, Wei Zhang, Khue Truong
  • Patent number: 10583166
    Abstract: Disclosed herein are recombinant protein scaffolds and recombinant multifunctional protein scaffolds for use in producing antigen-binding proteins In addition, nucleic acids encoding such recombinant protein scaffolds, recombinant multifunctional protein scaffolds, and antigen-binding proteins are provided Vectors and cells useful for expression of the described proteins are also provided, as are methods of use.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: March 10, 2020
    Inventors: Mark I. Greene, Hongtao Zhang, Xiaomin Song, Ramachandran Murali, Masahide Tone
  • Patent number: 10576158
    Abstract: An immune conjugate according to the present invention provides a pharmaceutical composition, which can be used in the target-oriented drug treatment by conjugating a dendron allowing a plurality of drugs to be bound to a surface thereof and a target-directed antibody, and especially, can deliver high concentrations of drugs in a tumor-specific manner to exhibit a strong anticancer effect by conjugating a hydrophilic dendron, to which a plurality of anticancer drugs are bound, to an antibody.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: March 3, 2020
    Assignee: ABION INC.
    Inventors: Young Deug Kim, Eun Ji Park, Yejin Kim, Young Kee Shin, Jun Young Choi
  • Patent number: 10556964
    Abstract: Provided are compositions comprising a MSBODY and a cytotoxic immune cell (e.g., Cytokine-induced killer cell) to form Armed Activated CIK cells (ACCs), wherein the MSBODY comprising a first antigen binding moiety that has specificity for a tumor antigen, and a second antigen binding moiety that binds to the cell. Provided are also methods preparing a composition comprising a MSBODY and a cytotoxic immune cell, and methods for treating patients with CIK cells armed with bispecific antibodies.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: February 11, 2020
    Assignee: Wuhan YZY Biopharma Co., Ltd.
    Inventors: Pengfei Zhou, Tao Wang, Liu Hu, Mi Huang, Lijuan Fang, Yang Liu
  • Patent number: 10556957
    Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: February 11, 2020
    Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B. V.
    Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
  • Patent number: 10537637
    Abstract: Checkpoint regulator antagonists that bind specifically to TIGIT, PD-1 and/or PD-L1 are disclosed. Also disclosed are methods of making and using the checkpoint regulator inhibitors, including monospecific, bispecific and trispecific checkpoint regulator antagonists thereof.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: January 21, 2020
    Assignee: Gensun Biopharma Inc.
    Inventors: Jackie Z. Sheng, Bo Liu
  • Patent number: 10538742
    Abstract: This invention relates to the methods for the identification and isolation of cancer stem cells from cultured cancer cell lines. Cell line-derived cancer stem cells isolated using the present methods may be useful, for example, in assays to screen compounds for anti-cancer stem cell activity and in target discovery methods for identifying novel expressed genes and druggable targets. The invention also relates to the screening of compounds for activity against cell line-derived cancer stem cells.
    Type: Grant
    Filed: November 12, 2005
    Date of Patent: January 21, 2020
    Assignee: Cambridge Enterprise Limited
    Inventor: Toru Kondo
  • Patent number: 10532109
    Abstract: Provided herein are therapeutic agents having specificity for having inhibitory activity against cancer cells that overexpress human epidermal growth factor receptor (HER) genes, including therapeutic agents comprising one or more HER-targeting peptides, pharmaceutical compositions comprising such therapeutic agents, and methods of using such compositions to treat or prevent a cancer or other disease condition associated with HER overexpression.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: January 14, 2020
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Shengxi Chen, Yanmin Zhang, Sidney Hecht
  • Patent number: 10533227
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: January 14, 2020
    Assignees: Millennium Pharmaceuticals, Inc., Board of Regents, University of Texas System
    Inventors: Ole Petter Veiby, Robert C. Bast, Gordon B. Mills, Gabriel N. Hortobagyi
  • Patent number: 10526387
    Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 7, 2020
    Inventors: Thorsten Klamp, Ugur Sahin, Ozlem Tureci, Michael Koslowski, Thomas Hiller, Jens Schumacher
  • Patent number: 10519248
    Abstract: Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: December 31, 2019
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Nai-Kong V. Cheung, Andres Lopez-Albaitero, Hong Xu
  • Patent number: 10517948
    Abstract: The present disclosure is directed to antibodies that bind to DC-HIL on the surface of myeloid-derived suppressor cells, and thus antagonize the T cell suppressor function of these cells, as well as their use in diagnosing and treating cancers such as melanoma.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: December 31, 2019
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Kiyoshi Ariizumi, Ponciano Cruz
  • Patent number: 10501541
    Abstract: The invention relates to compounds, in particular polypeptides that specifically bind to the non-classical MHC protein CD1d and modulate CD1d-mediated biological functions. The invention in particular relates to such compounds and polypeptides comprising or consisting of at least one single domain antibody, and wherein at least one single domain antibody specifically binds to CD1d. Also provided is for methods and use employing such compounds, polypeptides and/or single-domain antibodies.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: December 10, 2019
    Inventors: Johannes Jelle Van Der Vliet, Tanja Denise De Gruijl, Hendrik Marinus Willem Verheul, Renée Cornelia Gerarda De Bruin, Roeland Lameris
  • Patent number: 10501555
    Abstract: The present invention refers to humanized anti-Trop-2 antibodies and their fragments, derivatives and conjugates that are able to recognise and bind with high affinity distinct regions of the Trop-2 molecule. The present invention also teaches the use of such antibodies and of pharmaceutical compositions thereof for diagnosis and therapy of human pathologies, in particular cancer.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: December 10, 2019
    Inventors: Emanuela Guerra, Saverio Alberti
  • Patent number: 10487150
    Abstract: SIRPabodies comprise an immunoglobulin variable region, which may specifically bind a tumor antigen, viral antigen, etc., fused to a sequence comprising a binding domain of SIRP?. The binding domain of SIRP? comprises at least the N-terminal Ig-like domain of SIRP?, and may further comprise additional SIRP? sequences. The SIRPabodies find use in therapeutic methods that benefit from the combined activity of blocking CD47 activity, and antibody targeting, e.g. in the treatment of cancer, etc. In some specific embodiments, the SIRPabody comprises anti-CD20 activity and a SIRP? binding domain; anti-CD99 and a SIRP? binding domain; or anti-TIM3 activity and a SIRP? binding domain.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: November 26, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ravindra Majeti, Emily Piccione Griffin
  • Patent number: 10487366
    Abstract: The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease, prognostic evaluation and therapy of acute myeloid leukaemia (AML).
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: November 26, 2019
    Inventors: Brunangelo Falini, Cristina Mecucci
  • Patent number: 10487143
    Abstract: The invention generally relates to compositions and methods for preventing and treating cancer. More specifically, the invention relates to antigenic polypeptides and their use in cancer vaccines that may be used, in part, to treat cancer types dependent upon HER2-mediated signaling.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: November 26, 2019
    Assignee: Duke University
    Inventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
  • Patent number: 10457961
    Abstract: The present disclosure provides systems, compositions and methods for regulating expression of a target polynucleotide in a cell. The systems, compositions and methods comprise a chimeric receptor polypeptide comprising a G-protein coupled receptor (GPCR) or a fragment thereof, a chimeric adaptor polypeptide, at least one actuator moiety and a cleavage moiety.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: October 29, 2019
    Inventors: Lei S. Qi, P. C. Dave P. Dingal